Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 42Parkinson Disease 4, Autosomal Dominant Lewy Body 29Carcinoma, Renal Cell 26Endometrial Neoplasms 13Melanoma 10Neoplasms 8Uterine Cervical Neoplasms 7Cholangiocarcinoma 7Biliary Tract Neoplasms 7Liver Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Neuroendocrine Tumors 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Carcinoma, Anaplastic 3Recurrence 3Kidney Neoplasms 3Esophageal Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Adenoid Cystic 3Breast Neoplasms 3Brain Neoplasms 3Adenocarcinoma 3Vulvar Neoplasms 2

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cisplatin 4Carboplatin 4Biopsy 4trastuzumab deruxtecan 3Trastuzumab 3Platinum 3Goserelin 3Docetaxel 3sacituzumab govitecan 2pertuzumab 2entrectinib 2darolutamide 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1spartalizumab 1selinexor 1pyrotinib 1luprolide acetate gel depot 1lenvatinib 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × lenvatinib × 1 year × Clear all
NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
64 enrolled
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡